within Pharmacolibrary.Drugs.ATC.B;

model B01AF04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.34,
    Cl             = 5.733333333333333e-05,
    adminDuration  = 600,
    adminMass      = 80 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.032799999999999996,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005833333333333334,
    Tlag           = 30.0,            
    Vdp             = 0.016800000000000002,
    k12             = 7.2,
    k21             = 7.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AF04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Betrixaban is an oral, direct, selective inhibitor of factor Xa used as an anticoagulant to reduce the risk of venous thromboembolism (VTE) in adult patients. It has been approved for this indication in certain regions but is not widely marketed today, as the manufacturer discontinued its sale in recent years.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Murphy, G, et al., &amp; Chamoun, R (2018). Betrixaban: A Novel Oral Anticoagulant With a New Niche. <i>The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians</i> 34(3) 123–133. DOI:<a href=&quot;https://doi.org/10.1177/8755122518759765&quot;>10.1177/8755122518759765</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34861030/&quot;>https://pubmed.ncbi.nlm.nih.gov/34861030</a></p></li><li><p>Dunois, C (2021). Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). <i>Biomedicines</i> 9(5) –. DOI:<a href=&quot;https://doi.org/10.3390/biomedicines9050445&quot;>10.3390/biomedicines9050445</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33919121/&quot;>https://pubmed.ncbi.nlm.nih.gov/33919121</a></p></li><li><p>Grześk, G, et al., &amp; Banach, J (2021). The Clinical Significance of Drug-Food Interactions of Direct Oral Anticoagulants. <i>International journal of molecular sciences</i> 22(16) –. DOI:<a href=&quot;https://doi.org/10.3390/ijms22168531&quot;>10.3390/ijms22168531</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34445237/&quot;>https://pubmed.ncbi.nlm.nih.gov/34445237</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AF04;
